These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16405109)

  • 1. Influence of geomagnetic activity on mustophoran hematotoxicity.
    Blank MA; Blank OA; Gershanovich ML
    Dokl Biol Sci; 2005; 404():338-40. PubMed ID: 16405109
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II study of fotemustine in advanced soft tissue sarcomas. A trial of the EORTC Soft Tissue and Bone Sarcoma Group.
    Kerbrat P; Somers R; Verweij J; Crowther D; Tursz T; Santoro A; Steward WP; Lentz MA; van Glabbeke M; Mouridsen HT
    Eur J Cancer; 1992; 29A(1):143-4. PubMed ID: 1445732
    [No Abstract]   [Full Text] [Related]  

  • 3. [Toxic hematologic side effects of chemotherapy: nursing interventions].
    Schewski R
    Pflege Z; 2009 Aug; 62(8):466-9. PubMed ID: 19728437
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II study of nitrosourea fotemustine as single-drug chemotherapy in poor-prognosis non-small-cell lung cancer.
    Pujol JL; Monnier A; Berille J; Cerrina ML; Douillard JY; Rivière A; Grandgirard A; Gouva S; Bizzari JP; Le Chevalier T
    Br J Cancer; 1994 Jun; 69(6):1136-40. PubMed ID: 8198982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases.
    Jacquillat C; Khayat D; Banzet P; Weil M; Fumoleau P; Avril MF; Namer M; Bonneterre J; Kerbrat P; Bonerandi JJ
    Cancer; 1990 Nov; 66(9):1873-8. PubMed ID: 2224783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of nitrosourea fotemustine: a French cancer centre multicentric study.
    Iliadis A; Launay-Iliadis MC; Lucas C; Fety R; Lokiec F; Tranchand B; Milano G
    Eur J Cancer; 1996 Mar; 32A(3):455-60. PubMed ID: 8814692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of malignant melanoma with methyl CCNU.
    Young RC; Canellos GP; Chabner BA; Schein PS; Brereton HD; DeVita VT
    Clin Pharmacol Ther; 1974 Jun; 15(6):617-22. PubMed ID: 4601745
    [No Abstract]   [Full Text] [Related]  

  • 8. Mutagenicity to Salmonella, Drosophila and the mouse bone marrow of the human antineoplastic agent fotemustine: prediction of carcinogenic potency.
    Ashby J; Vogel EW; Tinwell H; Callander RD; Shuker DE
    Mutat Res; 1993 Mar; 286(1):101-9. PubMed ID: 7678906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toxicity of fotemustine in rat hepatocytes and mechanism-based protection against it.
    Vermeulen NP; Commandeur JN; Groot EJ; Wormhoudt LW; Ramnatshing S; Li QJ; Brakenhoff JP
    Chem Biol Interact; 1998 Apr; 110(3):139-58. PubMed ID: 9609383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCNU (NSC-79037): preclinical toxicologic evaluation of a single intravenous infusion in dogs and monkeys.
    Schaeppi U; Fleischman RW; Phelan RS; Ethier MF; Luthra YK
    Cancer Chemother Rep 3; 1974 Sep; 5(1):53-64. PubMed ID: 4213020
    [No Abstract]   [Full Text] [Related]  

  • 11. Allopurinol and cytotoxic drugs. Interaction in relation to bone marrow depression. Boston Collaborative Drug Surveillance Program.
    JAMA; 1974 Mar; 227(9):1036-40. PubMed ID: 4405931
    [No Abstract]   [Full Text] [Related]  

  • 12. Lomustine treatment of metastatic renal cell carcinoma.
    Mittelman A; Albert DJ; Murphy GP
    JAMA; 1973 Jul; 225(1):32-5. PubMed ID: 4740302
    [No Abstract]   [Full Text] [Related]  

  • 13. Logistic regression model of fotemustine toxicity combining independent phase II studies.
    Raymond E; Haon C; Boaziz C; Coste M
    Cancer; 1996 Nov; 78(9):1980-7. PubMed ID: 8909320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of CCNU (NSC-79037) in the treatment of advanced gastrointestinal cancer.
    Klaassen DJ; Rapp E
    Cancer Chemother Rep; 1974; 58(5 Pt 1):667-9. PubMed ID: 4426046
    [No Abstract]   [Full Text] [Related]  

  • 15. A trial of 1-(2-chlorethyl)-3-(4-methyl-cyclohexyl)-1-nitrosourea in the treatment of patients with advanced gastro-intestinal cancer.
    Giles GR; Hall R; Brennan TG; Worthy TS
    Br J Surg; 1974 Dec; 61(12):950. PubMed ID: 4140746
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of advanced Hodgkin's disease with (1,3 bis (2-chloroethyl)-1-nitrosourea) BCNU.
    Young RC; DeVita VT; Serpick AA; Canellos GP
    N Engl J Med; 1971 Aug; 285(9):475-9. PubMed ID: 5558887
    [No Abstract]   [Full Text] [Related]  

  • 17. Persistent thrombocytopenia during melanoma treatment with fotemustine.
    Turrisi G; Sozzi P; Marinozzi C; Clerico MA
    Melanoma Res; 2006 Dec; 16(6):543-4. PubMed ID: 17119456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
    Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
    Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Qualitative and quantitative toxicity of sublethal doses of methyl-CCNU in BDF1 mice.
    Denine EP; Harrison SD; Peckham JC
    Cancer Treat Rep; 1977; 61(3):409-17. PubMed ID: 872140
    [No Abstract]   [Full Text] [Related]  

  • 20. 1-2(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU, NSC-79037): a comparison of drug administration at four-week and six-week intervals.
    Broder LE; Hansen HH
    Eur J Cancer (1965); 1973 Feb; 9(2):147-52. PubMed ID: 4717488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.